Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Hemophagocytic Lymphohistiocytosis
NCT05320575Phase 3Completed
- Sponsor
- Beijing Friendship Hospital
- Start
- Feb 2022
- Primary completion
- Aug 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 3 trial of zanubrutinib in hemophagocytic lymphohistiocytosis (HLH), sponsored by Beijing Friendship Hospital. Started Feb 2022; status: completed.
02
Drugs
zanubrutinib
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT05320575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320575.